RTW INVESTMENTS, LPRTW INVESTMENTS, LP

Institutional investor · Portfolio as of Q2 2021

SEC EDGAR SourceSEC Filings

Top Holdings113 positions

Checking export access…
Activity:
Stock
Shares
Value
Weight
Avg Buy
Est. P&L
Held
Conviction

ROCKET PHARMACEUTICALS INC

15M$663.9M10.0%$18.09+139.51%
10 qtrssince 2019-Q1
Decreased
0
SPYSPY
Unit

STATE STREET SPDR S&P 500 ETF TRUST CL USD INC

996,255$426.5M6.4%$371.30+8.23%
2 qtrssince 2021-Q1
Increased
64

ALNYLAM PHARMACEUTICALS INC

1.7M$285.4M4.3%$81.30+104.03%
10 qtrssince 2019-Q1
Unchanged
0
DRNADRNADelisted

DICERNA PHARMACEUTICALS INC

7.5M$280.7M4.2%
10 qtrssince 2019-Q1
Increased
57

VERICEL CORP

4.5M$237.2M3.6%$17.25+234.99%
10 qtrssince 2019-Q1
Unchanged
0
MRTXMRTXDelisted

MIRATI THERAPEUTICS INC

1.5M$235.4M3.6%
10 qtrssince 2019-Q1
Increased
62

ILLUMINA INC

482,791$228.5M3.4%$334.89+39.19%
4 qtrssince 2020-Q3
Increased
56

PTC THERAPEUTICS INC

5.3M$223.8M3.4%$41.64+0.91%
10 qtrssince 2019-Q1
Unchanged
0

ESTABLISHMENT LABS HLDGS INC

2.3M$202.6M3.1%$21.90+295.58%
10 qtrssince 2019-Q1
Unchanged
0
MASIMASIDelisted

MASIMO CORP

826,210$200.3M3.0%$193.01+27.91%
10 qtrssince 2019-Q1
Increased
74

NATERA INC

1.7M$194.4M2.9%$37.29+212.07%
8 qtrssince 2019-Q3
Unchanged
0

PROTAGONIST THERAPEUTICS INC

3.5M$157.4M2.4%$11.38+287.62%
8 qtrssince 2019-Q3
Unchanged
0

10x Genomics Inc Class A

734,481$143.8M2.2%$89.68+124.49%
8 qtrssince 2019-Q3
Increased
54

Celldex Therapeutics, Inc.

3.9M$130.7M2.0%$14.15+149.90%
5 qtrssince 2020-Q2
Unchanged
0
DMTKQDMTKQDelisted

DERMTECH INC

3.1M$129.6M2.0%
8 qtrssince 2019-Q3
Unchanged
0

GLOBUS MED INC

1.7M$129.5M2.0%$64.85+17.75%
3 qtrssince 2020-Q4
Unchanged
0
AXNXAXNXDelisted

AXONICS INC

1.9M$123.3M1.9%
10 qtrssince 2019-Q1
Increased
49

STOKE THERAPEUTICS INC

3.6M$122.7M1.9%$29.30+12.65%
9 qtrssince 2019-Q2
Unchanged
0

Guardant Health, Inc.

918,253$114M1.7%$119.70+6.76%
4 qtrssince 2020-Q3
Increased
66

QUIDEL CORP

878,533$112.6M1.7%$126.39-88.46%
2 qtrssince 2021-Q1
Unchanged
0
$6.6B
AUM
113
Positions
Q2 2021
Filing
Rating · 3.0
Quarterly Portfolio Change
-12%Q1'20$2.3B+53%Q2'20$3.6B+17%Q3'20$4.2B+44%Q4'20$6B+7%Q1'21$6.4B+3%Q2'21$6.6B
Activity profile
$ moved · Q2'21
New12%Increased40%Decreased13%Exited35%
Composition
Equity vs derivatives
Equity100%Puts0%Calls0%
Holding period
Avg 1.1 years
<1Q12%1-4Q38%1-2Y24%2Y+26%

RTW INVESTMENTS, LP manages $6.6B across 113 positions as of Q2 2021. Top holdings: RCKT (10.0%), SPY (6.4%), ALNY (4.3%). Fund DNA: Diversified Scout. HoldingsIntel Rating: 3/5.0.

Q2 2021 Summary

Active quarter - 15 new positions, 13 exits, 21 increased. Top move: MASI (INCREASED, conviction 74). Portfolio: $6.6B across 113 positions.

Top holdings by portfolio weight

Total AUM$7B
RCKT10.02%
SPY6.44%
ALNY4.31%
DRNA4.24%
VCEL3.58%
MRTX3.55%
ILMN3.45%
PTCT3.38%
ESTA3.06%
MASI3.02%
Other2.93%

Portfolio allocation by GICS sector

Sectors2
Healthcare71.34%
Unknown28.66%

Behavioral investing profile

Checking access…
Diversified Scout- primarily Healthcare, Unknown
Compare DNA across all funds
7-dimension quality assessment
Solid(3.0 / 5.0)
Track Record36
Conviction45
Concentration72
Checking access…

Position Outcomes

Best and worst performing positions by estimated return

Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.

Similar Funds

Funds with similar investing DNA

Accumulation Streaks

Positions with 2+ consecutive quarters of increases - persistent directional conviction.

Security
7Q
RDNTRDNTRadNet, Inc.
Q4 2024 Q2 2026+3M shares+$173.4M
6Q
CMPSCMPSCOMPASS PATHWAYS PLC
Q1 2025 Q2 2026+7.6M shares+$139.7M
6Q
IMTXIMTXIMMATICS N.V
Q1 2025 Q2 2026+6.4M shares+$84.6M
Checking access…

Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used